Articles that mention Allergan -BoardProspects

Allergan

0 Comments Leave a Comment

1-15 of 26 1 2 »
1. Mentioned In 26 Articles
2. A Handful of Allergan's Top Shareholders Want to Bring Back the Old CEO as Chairman
  
  Explore Business Insider Jun 7 2018 BoardNews
  
  ...est Allergan holders. A spokeswoman for Allergan declined to comment. Pyott, who served as chief executive of Allergan from 1998 to 2015, declined to comment when Business Insider asked him if he was interested in a new ...
  Read Full Article
  
  Comment
  
  Mentions: Investment Management Investors
3. Allergan Responds to Public Shareholder Letter
  
  Explore Stock Market Jun 5 2018 BoardNews
  
  ..., including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by ...
  Read Full Article
  
  Comment
  
  Mentions: National Association of Corporate Directors Management NYSE
4. Hedge Fund Appaloosa Asks Allergan to Split Chairman-CEO Position
  
  Explore reuters.com Jun 5 2018 BoardNews
  
  ...ionaire investor David Tepper’s hedge fund Appaloosa Management and Senator Investment Group on Tuesday asked Allergan Plc’s (AGN.N) board to split the office of the chief executive officer and chairman. In May, Appaloos...
  Read Full Article
  
  Comment
  
  Mentions: Investment Management CEO
5. Now that Ironwood's Spinning off R&D, Activist Alex Denner is Easing Up
  
  Explore Pharma News Jun 1 2018 BoardNews
  
  ...hang onto its treatments for GI diseases, gout and abdominal pain—including Linzess, a product it shares with Allergan—as well as a candidate for gastroesophageal reflux disease. The new company’s pipeline, meanwhile, wi...
  Read Full Article
  
  Comment
  
  Mentions: Credit Suisse Carl Icahn Sarissa
6. Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne
  
  Explore CNBC.com May 29 2018 BoardMoves
  
  ... and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. (NYSE:AGN), he oversaw financial due diligence, integration and structuring for more than 100 a...
  Read Full Article
  
  Comment
  
  Mentions: Board of Trustees Leadership Technology
7. Appaloosa Gets Permission for Activist Stance with Allergan Stake
  
  Explore reuters.com May 17 2018 BoardNews
  
  ...r they want take an activist approach to the investment or not.” Tepper’s Appaloosa LP increased its stake in Allergan to 3.7 million shares from around 3.5 million shares over the last quarter, the firm said in a filing...
  Read Full Article
  
  Comment
  
  Mentions: Conference Investment Activist Investors
8. Allergan (AGN) Announces Election of John Davidson to Board
  
  Explore StreetInsider.com May 3 2018 BoardMoves
  
  ...has been elected to its Board of Directors . Mr. Davidson and the other directors standing for re-election to Allergan's Board were elected at Allergan's Annual General Meeting of Shareholders on May 2, 2018. With the ad...
  Read Full Article
  
  Comment
  
  Mentions: NYSE Allergan John Davidson
9. Investors are Angry with Botox-Maker Allergan — and They're Trying to Get an Activist Involved to Shake It Up
  
  Explore Business Insider Apr 26 2018 BoardNews
  
  ... if any major activist investor has taken a stake in Allergan in the last several weeks. A representative for Allergan could not be reached for comment. Allergan CEO Brent Saunders said at a March investor conference tha...
  Read Full Article
  
  Comment
  
  Mentions: Activist Investors Investors CEO
10. Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors
  
  Explore businesswire.com Apr 24 2018 BoardMoves
  
  ...and Head of Corporate Development at Tobira Therapeutics, a publicly-traded biotechnology company acquired by Allergan in November 2016. Prior to joining Tobira Therapeutics, he held senior management roles at Jennerex B...
  Read Full Article
  
  Comment
  
  Mentions: Investors acquisition Amgen
11. 'Losing direction': Allergan Investors are Unhappy After a Wild 4 Hour Takeover Drama
  
  Explore Business Insider Apr 19 2018 BoardNews
  
  ...t chronic dry eye, was approved in 2003. In 2017, the drug made $1.4 billion in sales, making up about 20% of Allergan's profits. Allergan's also facing potential competition to Botox, its blockbuster drug that made $2.2...
  Read Full Article
  
  Comment
  
  Mentions: Investors CEO Takeover
12. Allergan and Takeda May Fight Over Shire
  
  Explore The New York Times Apr 19 2018 BoardNews
  
  ...Shire said that they are in discussions, which could lead to yet another revised bid. Yet for both Takeda and Allergan, a deal for Shire could prove financially risky, since each company would need to borrow significant ...
  Read Full Article
  
  Comment
  
  Mentions: Corporate Governance Management I.P.O.
13. Valeant CEO Papa says Drugmaker has 'Turnaround Opportunity of a Lifetime'
  
  Explore bnn.ca Jan 10 2018 BoardNews
  
  ...reed to settle investor claims that they engaged in insider trading in the unsuccessful 2014 takeover bid for Allergan. To contact the reporters on this story: Jared S. Hopkins in New York at jhopkins38@bloomberg.net, Cy...
  Read Full Article
  
  Comment
  
  Mentions: Conference CEO Bill Ackman
14. Pershing Square, Valeant Arrive at Settlement Split for Allergan Lawsuit
  
  Explore reuters.com Dec 30 2017 BoardNews
  
  ... the two months before Pershing Square Capital Management and Valeant made an unsolicited $51 billion bid for Allergan. reut.rs/2DwW6XN Actavis Plc eventually bought Allergan in 2015, taking its name. Both Pershing Squar...
  Read Full Article
  
  Comment
  
  Mentions: Management CEO Bill Ackman
15. Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva
  
  Explore biospace.com Nov 6 2017 BoardNews
  
  ...es of Teva. Last week, the Irish company said it will begin to sell off the 10 percent stake it owns in Teva. Allergan acquired the chunk of Teva stock in its 2015 $40.5 billion sale of Actavis, its generics business to ...
  Read Full Article
  
  Comment
  
  Mentions: CEO Teva Pharmaceuticals stake
16. Juniper Pharmaceuticals Appoints Jennifer Good to Board of Directors
  
  Explore PR Newswire Sep 12 2017 BoardMoves
  
  ...he U.S. and EU. CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S. Forward Looking Statements This press release contains "forward-looking statements" w...
  Read Full Article
  
  Comment
  
  Mentions: Corporate Governance Management CEO
17. 1-15 of 26 1 2 »